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Studies using cell lines should always characterize these cells to ensure that the results are not distorted 
by unexpected morphological or genetic changes possibly due to culture time or passage number. 
Thus, the aim of this study was to describe those MIA PaCa-2 and PANC-1 cell line phenotype and 
genotype characteristics that may play a crucial role in pancreatic cancer therapeutic assays, namely 
neuroendocrine chemotherapy and peptide receptor radionuclide therapy. Epithelial, mesenchymal, 
endocrine and stem cell marker characterization was performed by immunohistochemistry and flow 
cytometry, and genotyping by PCR, gene sequencing and capillary electrophoresis. MIA PaCa-2 
(polymorphism) expresses CK5.6, AE1/AE3, E-cadherin, vimentin, chromogranin A, synaptophysin, 
SSTR2 and NTR1 but not CD56. PANC-1 (pleomorphism) expresses CK5.6, MNF-116, vimentin, 
chromogranin A, CD56 and SSTR2 but not E-cadherin, synaptophysin or NTR1. MIA PaCA-1 is CD24−, 
CD44+/++, CD326−/+ and CD133/1− , while PANC-1 is CD24−/+, CD44+, CD326−/+ and CD133/1−. Both cell 
lines have KRAS and TP53 mutations and homozygous deletions including the first 3 exons of CDKN2A/
p16INK4A, but no SMAD4/DPC4 mutations or microsatellite instability. Both have neuroendocrine 
differentiation and SSTR2 receptors, precisely the features making them suitable for the therapies we 
propose to assay in future studies.
Pancreatic ductal adenocarcinoma accounts for over 90% of all pancreatic cancers1 and is now the fourth lead-
ing cause of cancer-related death in the western world2,3. The prognosis is extremely poor, with a 5-year relative 
survival rate of 5%2 and median survival of 3.5 months for non-resectable tumors4. Surgical resection is the only 
potentially curative therapy5, but even in these cases relapses are common6.
Pancreatic ductal adenocarcinomas can display disseminated neuroendocrine cells. However, the relative 
incidence, histogenesis, hormone production and prognostic implications of their presence are controversial7. 
Antibodies against the neural cell adhesion molecule (NCAM or CD56), neuronspecific enolase (NSE), synapto-
physin, CD57 and chromogranin A (CGA) can be used for immunostaining and identification of neuroendocrine 
cells in pancreatic ductal adenocarcinoma7,8.
Although the putative cell of origin for pancreatic cancer remains elusive, within hematopoietic and solid 
tumors minor subpopulations of cells with a self-renewing capacity, also termed cancer stem cells (CSCs), have 
been identified, which appear to be responsible for tumor initiation, growth, metastases and resistance to con-
ventional therapies9. Different subpopulations of cancer stem cells have been identified in pancreatic ductal ade-
nocarcinoma, based on the use of a combination of surface markers, such as CD44, CD24, EpCAM (Epithelial 
Cell Adhesion Molecule), also known as ESA (Epithelial Cell Surface Antigen), CD326, CD133 and others, such 
as side population (SP) cells with overexpression of ABCG2 transporters and CXCR4. These markers allow CSC 
isolation, propagation and characterization10 to be carried out.
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CSCs may be dependent on the phenotype for epithelial-mesenchymal transition (EMT) , a primordial devel-
opmental process by which adult polarized epithelial cells undergo biochemical changes and assume a mesenchy-
mal phenotype, acquiring an increased migratory capacity, invasiveness, resistance to apoptosis and expression of 
extracellular matrix components11. This dedifferentiation process is associated with a loss of functional epithelial 
cell markers, such as E-cadherin, and increased expression of mesenchymal markers, such as vimentin12. EMT 
has also been demonstrated to correlate with CD24+CD44+ and CD133+ cells in pancreatic cancer, providing 
pancreatic cancer stem cells with a strong migratory capacity, while maintaining their ability to multiply and thus 
allowing the production of progenies during metastasis13.
Within pancreatic cells, the accumulation of genetic changes leads to a multi-staged process giving rise to 
malignancy. Mutations in the proto-oncogene KRAS and tumor suppressors CDKN2A, TP53 and SMAD4/DPC4 
are major genetic alterations associated with cell cycle deregulation, apoptosis inhibition, invasion, metastasis and 
poor treatment response14. Microsatellite instability (MSI) is a genetic feature of sporadic and familial cancers 
of multiple sites and is related to defective mismatch repair (MMR) protein function15. It has been described in 
pancreatic cancer and studies suggest that MSI may be associated with KRAS mutations16. Other investigations 
propose that MSI-positive pancreatic cancers may have a better prognosis after resection because of the intense 
immunoreaction to the tumor17. Furthermore, the risk of developing a pancreatic tumor is 8.6 times more in 
patients with Lynch syndrome compared to the general population18. In these patients , a c.2252_2253delAA 
MLH1 mutation associated with an increased risk of pancreatic tumors19 was found, and another in the MSH2 
gene associated with an intraductal papillary mucinous neoplasm20 was also discovered.
The existence of adenocarcinomas with neuroendocrine differentiation (NED) may provide the possibility of 
treating this subgroup of tumors with peptide receptor radionuclide therapy, alone or associated with other forms 
of treatment, such as chemotherapy21. This option of treatment requires the presence of high affinity receptors 
on tumoral cells, such as somatostatin receptors (SSTRs)22. Five different subclasses of these receptors , SSTR1 
to 5, have been cloned and characterized, but in the majority of neuroendocrine gastroenteropancreatic tumors, 
SSTR2 and SSTR5 predominate23. The synthesis of somatostatin analogs, such as octreotide, has led to them being 
used in therapy in radiolabeled form24. 90Y [90Y-DOTA (tetraazacyclododecane-1,4,7,10-tetracetic acid)–TOC 
(Tyr3-octreotide)], a pure β emitter, and 177Lu [177Lu-DOTA-TATE (Tyr3-octreotate)], a β and γ emitter, are cur-
rently the most widely used radionuclides in the treatment with somatostatin analogs25.
Neurotensin receptors (NTRs) are present in the large majority of pancreatic ductal adenocarcinomas, but 
absent in endocrine pancreatic cancers, chronic pancreatitis and normal pancreatic acini26. Neurotensin is a 
13-amino-acid peptide found in both the central nervous system and peripheral tissues, mainly in the gastroin-
testinal tract. At least three subtypes of NTRs have been cloned: NTR1, NTR2 and sortilin/NTR327. One clinical 
evaluation study using a radiolabeled NT analog (99 mTc-NT-XI) included four exocrine pancreatic carcinoma 
patients, with moderate tumor uptake being observed in only one patient28. More recently, NTR1 was assumed to 
be a potential target for pharmacological therapy29, and in another study an 18F-labeled diarylpyrazole glycocon-
jugate obtained excellent stability and highly beneficial biodistribution in vivo, as demonstrated by PET imaging 
in HT-29 tumor bearing nude mice, representing a highly promising candidate for PET imaging of NTR1 positive 
tumors30.
MIA PaCa-2 with functional SSTR2 receptors31 and PANC-1 cell lines are primary tumors currently used 
as in vitro models to study pancreatic ductal adenocarcinoma carcinogenesis. Their morphological and genetic 
characteristics are well studied. However, studies using cell lines should always characterize these cells to ensure 
that the results are not distorted by unexpected morphological or genetic changes possibly due to culture time 
or passage number. Thus, the aim of this study was to confirm and investigate MIA PaCa-2 and PANC-1 cell line 
phenotype and genotype characteristics that may be relevant for their use as in vitro models in pancreatic cancer 
neuroendocrine chemotherapy and peptide receptor radionuclide therapy assays.
Results
Immunohistochemistry. Microscopic observation of MIA PaCa-2 cells revealed the presence of two dis-
tinct morphological patterns (Fig. 1): large cells and small cells (morula). The MIA PaCa-2 cell line expresses 
(Table 1): CK5.6 (Fig. 1A), AE1/AE3 (Fig. 1B), E-cadherin (Fig. 1C), vimentin (Fig. 1D), chromogranin A 
(Fig. 1E) and synaptophysin (Fig. 1F) but not CD56. It also expresses SSTR2 (Fig. 1G) and NTR1 (Fig. 1H).
Microscopic observation of PANC-1 cells revealed the presence of three distinct morphological patterns 
(Fig. 2): large cells (isolated), intermediate cells (stellate) and small cells (morula). The PANC-1 cell line expresses 
(Table 2): CK5.6 (Fig. 2A), AE1/AE3 (Fig. 2B), vimentin (Fig. 2C), chromogranin A (Fig. 2D), CD56 (Fig. 2E) and 
SSTR2 (Fig. 2F) but not E-cadherin, synaptophysin or NTR1.
Flow cytometry. Immunophenotyping of MIA PaCa-2 and PANC-1 cell lines revealed differences in mor-
phology and immunohistochemistry. Flow cytometry was employed to clarify whether, in morphological terms, 
there were in fact two cell populations in MIA Paca-2 and three in PANC-1. This technique was also used to char-
acterize these cell lines in terms of the presence of pancreatic stem cell markers, such as CD24, CD44, CD133/1 
and CD326.
The MIA PaCa-2 results (Fig. 3) demonstrated the presence of three groups of gated cells based on FSC vs. 
SSC characteristics (Fig. 3A): red (P1), green (P2) and blue (P3) populations, supporting the possibility of the 
existence of a polymorphic cell line. We obtained a total of 20,000 events, with P1 representing 2,539 events, cor-
responding to 12.7% of cells, with a Mean Fluorescence Intensity (MFI) of 5,559; P2, 12,868 events, 64.3% of cells, 
with an MFI of 12,158; and P3, 2,322 events, 11.6% of cells, with an MFI of 20,031. The smaller and less complex 
P1 (red) population stained positive with cell viability staining solution 7AAD (Fig. 3B), confirming that this 
group was composed of non-viable cells, while the population of small cells (green, P2) and large cells (blue, P3) 
stained negative for 7AAD, demonstrating that P2 and P3 are composed of viable cells.
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Figure 1. MIA PaCa-2: Immunohistochemistry. (A) CK 5.6 × 200; (B) AE1/AE3 × 200; (C) E-cadherin × 400; 
(D) Vimentin × 400; (E) Chromogranin A × 400; (F) Synaptophysin × 400; (G) SSTR2 × 400; (H) NTR1 × 400. 
Small single cells (blue arrow); small clustered cells (green arrow); large single cells (red arrow); large clustered 
cells (orange arrow). Scale bar: 10 μ m.
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Marker Morphology Result Morphology Result
CK 5.6 Large cells + + + Small cells (morula) + + 
AE1/AE3 Large cells + + + Small cells (morula) + + + 
E-cadherin Large cells + + + Small cells (morula) + + + 
Vimentin Large cells + + + Small cells (morula) + + 
Chromogranin A Large cells − /+ Small cells (morula) + + + 
CD 56 Large cells − /+ Small cells (morula) − 
Synaptophysin Large cells + Small cells (morula) − 
SSTR2 Large cells + + + Small cells (morula) + + + 
NTR1 Large cells + + Small cells (morula) + + 
Table 1.  MIA PaCa-2 immunohistochemical profile. Cut off: − (0%); + (< 10%); + + (10–75%); + + + 
(> 75%).
Figure 2. PANC-1: Immunohistochemistry. (A) CK 5.6 × 400; (B) AE1/AE3 × 200; (C) Vimentin × 200;  
(D) Chromogranin A × 400; (E) CD56 × 400; (F) SSTR2 × 400. Small cells (blue arrow); intermediate cells 
(green arrow); large cells (red arrow). Scale bar: 10 μ m.
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To investigate the presence of stem cells, further flow cytometry studies were then conducted using spe-
cific MIA PaCa-2 stem cell markers such as CD24 PE (Fig. 3C), CD44 PerCP/Cy5.5 (Fig. 3D), CD133/1 APC 
(Fig. 3E) and CD326 PE-Cy7 (Fig. 3F,G). The results showed a lack of expression for CD24 (CD24−) (Fig. 3C) 
and CD133/1 (CD133/1−) (Fig. 3D). The large cell (blue) population showed higher levels of CD44 (Fig. 3D), 
represented as a CD44++ phenotype, and higher MFI (70.9) than the small cell (green) population, which showed 
a CD44+ phenotype and lower MFI (32.9) (Fig. 3D). The experiment was repeated with another fluorochrome 
(APC) (Fig. 3H) and the result was the same. In addition, concerning CD326 expression, it can be seen in Fig. 3F 
that the large cell population is mainly CD326− and in Fig. 3G the small cell population is CD326−/+. Thus, it 
seems that the large cell population has the phenotype CD24−CD44++CD326−CD133/1− and the small cell pop-
ulation, CD24−CD44+CD326−/+CD133/1−, making the subpopulations of the MIA PaCa-2 cell line phenotypi-
cally distinct. In Fig. 3I we can see the relation between CD326 and CD44 and the distribution of the MIA PaCa-2 
viable cell population according to four possible phenotypes: Q1 (blue), CD44−CD326+, comprising 6.9% of total 
cells; Q2 (purple), CD44+CD326+, 35.5% of cells; Q3 (brown), CD44−CD326−, 9.6% of cells; and Q4 (green), 
CD44+CD326−, 48% of cells. Thus, in the MIA PaCa-2 cell line, there is an overwhelming predominance of the 
phenotypes CD44+CD326− (48%) and CD44+CD326+ (35.5%).
When performing the same study in the PANC-1 cell line (Fig. 4), while in optic microscopy and immunohis-
tochemistry we observed three distinct populations, flow cytometry dot plot FSC/SSC revealed the existence of 
only one population of viable cells (P1). In fact, in 10,000 events, a population (P1) with 6,888 events was obtained 
(Fig. 4A), corresponding to 68.9% of total cells, with an MFI of 1,192, supporting the possibility of the existence 
of a pleomorphic cell line. To investigate the presence of stem cells using CD24 FITC, CD44 APC, CD133/1 PE 
and CD326 PE-Cy7, we have characterized this population (P1) in relation to each marker and performed the 
gates P2, P3, P4 and P5. P2 corresponds to a subpopulation expressing CD24 (Fig. 4B), comprising 23.4% of P1, 
with an MFI of 3,502; P3 corresponds to a subpopulation expressing CD133/1 (Fig. 4C), 0.7% of P1, with an MFI 
of 3,324; P4 corresponds to a subpopulation expressing CD326 (Fig. 4D), 49.1% of P1, with an MIF of 2,068; and 
P5 corresponds to a subpopulation expressing CD44 (Fig. 4E), 92.3% of P1, with an MFI of 1,186. PANC-1 cells 
seem to have the phenotype CD24−/+, CD44+, CD326−/+ and CD133/1−.
Genetic profile. The genotyping of MIA PaCa-2 (Fig. 5) confirmed the presence of a homozygous missense 
mutation in codon 12 (p.G12C; GGT > TGT) of KRAS (Fig. 5A), a homozygous deletion encompassing exons 
1, 2 and 3 of the CDKN2A/p16INK4A gene (Fig. 5B) and a homozygous missense mutation in exon 7 (p.R248W; 
CGG > TGG) of TP53 (Fig. 5C). Sequencing analysis did not identify any mutation in SMAD4/DPC4, nor was 
any microsatellite instability found.
The genotyping of PANC-1 (Fig. 6) revealed a heterozygous missense mutation in codon 12 (p.G12D; 
GGT > GAT) of KRAS (Fig. 6A), a homozygous deletion of exons 1, 2 and 3 of the CDKN2A/p16INK4A gene 
(Fig. 5B) and two missense variants in the TP53 gene, one in exon 4 (p.P72R; CCC > CGC) (Fig. 6B) and another 
in exon 8 (p.R273H; CGT > CAT) (Fig. 6C). As with the MIA PaCa-2 cell line, no SMAD4/DPC4 mutation was 
found by sequencing and no microsatellite instability was highlighted.
Discussion
Microscopic observation of MIA PaCa-2 cells revealed (Fig. 1) the presence of two distinct morphological pat-
terns: large cells and small cells (morula), while such observation of PANC-1 cells revealed (Fig. 2) the presence of 
three distinct morphological patterns: large cells (isolated), intermediate cells (stellate) and small cells (morula). 
Flow cytometry was used to clarify whether in morphological terms there were in fact two cell populations in 
MIA Paca-2 and three in PANC-1. MIA PaCa-2 flow cytometry results (Fig. 3) demonstrated the presence of two 
groups of viable cells: the population of large cells (blue) and that of small cells (green). This result may support 
the possibility that a polymorphic cell line exists. PANC-1 flow cytometry results demonstrated the presence of 
only one population of viable cells, supporting the possibility that a pleomorphic cell line exists. However, since 
there are no specific markers of pancreatic tumor cells, it cannot be stated with absolute certainty that this is a case 
of polymorphism for cell line MIA PaCa-2 and pleomorphism for cell line PANC-1.
The MIA PaCa-2 cell line (Table 1 and Fig. 1) expresses CK5.6, AE1/AE3, E-cadherin, vimentin, chromo-
granin A, synaptophysin, SSTR2 and NTR1, but not CD56. These cells are epithelial as they express CK5.6, 
AE1/AE3 and E-cadherin, with mesenchymal characteristics because they express vimentin, neuroendocrine 
Marker Morphology Result Morphology Result Morphology Result
CK 5.6 Large cells + + Intermediate cells (stellate) + + Small cells (morula) − 
AE1/AE3 Large cells + + Intermediate cells (stellate) + + Small cells (morula) + + + 
E-cadherin Large cells − Intermediate cells (stellate) − Small cells (morula) − 
Vimentin Large cells + + Intermediate cells (stellate) + + Small cells (morula) + + + 
Chromogranin A Large cells + Intermediate cells (stellate) + Small cells (morula) − 
CD 56 Large cells + Intermediate cells (stellate) + Small cells (morula) − 
Synaptophysin Large cells − Intermediate cells (stellate) − Small cells (morula) − 
SSTR2 Large cells + * Intermediate cells (stellate) + Small cells (morula) + + 
NTR1 Large cells − Intermediate cells (stellate) − Small cells (morula) − 
Table 2.  PANC-1 immunohistochemical profile. Cut off: − (0%); + (< 10%); + + (10–75%); + + + (> 75%); 
*polarized cytoplasm.
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differentiation since they express chromogranin A and synaptophysin, and hormonal receptors because they 
express SSTR2 and NTR1. The presence of SSTR2 and NTR1 may enable peptide receptor radionuclide therapy 
to be used in this cell line.
PANC-1 cells (Table 2 and Fig. 2) do not express E-cadherin, synaptophysin or NTR1. They are cells with epi-
thelial characteristics since they express CK5.6 and AE1/AE3, mesenchymal characteristics because they express 
vimentin, neuroendocrine differentiation as they express chromogranin A and CD56, and hormonal receptors 
because they express SSTR2. The presence of SSTR2 may allow peptide receptor radionuclide therapy to be used 
in this cell line.
If we compare the immunohistochemical pattern of these two cell lines (Tables 1 and 2), we notice that it is 
different, not only due to the absence of expression of certain markers and receptors, but also because of the vari-
able expression of others. Thus, in the large cells of MIA PaCa-2 there is a more pronounced expression of CK5.6, 
AE1/AE3, E-cadherin, vimentin, synaptophysin, SSTR2 and NTR1. The large cells of PANC-1, on the other hand, 
have a more pronounced expression of chromogranin A and CD56. In the small cells of MIA PaCa-2 there is a 
more pronounced expression of CK5.6 and AE1/AE3, and to an even greater extent E-cadherin, chromogranin A 
and NTR1. In the small cells of PANC-1 there is a more pronounced expression of vimentin. This difference in cell 
marker and receptor expression between large and small cells in the same cell line, and between large and small 
cells in both cell lines, enhances the concept of population variability.
Figure 3. Flow cytometry analysis of morphology and stem cell marker expression on MIA PaCa-2 tumor 
cells. (A) Dot plot FSC/SSC representative of the populations P1 (red), P2 (green) and P3 (blue); (B) Histogram 
representative of 7AAD expression; (C) Histogram representative of CD24 expression; (D) Histogram 
representative of CD44 expression (fluorochrome PerCP/Cy5.5); (E) Histogram representative of CD133 
expression; (F) Histogram representative of CD326 expression in P3; (G) Histogram representative of CD326 
expression in P2; (H) Histogram representative of CD44 expression (fluorochrome APC); (I) CD44/CD326 
expression.
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Concerning NED, MIA PaCa-2 expressed chromogranin A and synaptophysin (Table 1), and PANC-1 
expressed chromogranin A and CD56 (Table 2). In pancreatic carcinoma NED has been closely associated with 
tumor behavior: patients with tumors harboring NED have a better overall survival and NED seems to be an 
independent predictor of survival after surgery7. Both cell lines expressed chromogranin A, and this observation 
reveals NED to be associated with a better prognosis32,33.
Both MIA PaCa-2 and PANC-1 cells expressed epithelial markers CK5.6 and AE1/AE3, and the mesenchymal 
marker vimentin, allowing them to be characterized as epithelial-mesenchymal cells. The activation of an EMT 
program is the essential mechanism for the acquisition of a malignant phenotype by epithelial cancer cells, and 
the hallmark of EMT is the loss of the epithelial homotypic adhesion molecule E-cadherin and gain of mesenchy-
mal marker vimentin34. PANC-1 had no E-cadherin expression. It has been demonstrated that EMT contributes 
to drug resistance in pancreatic cancer and that increased expression of E-cadherin is associated with improved 
survival in several tumor types35. In some reports of migration assays, it was demonstrated that migration of 
PANC-1 cells was greater than MIA PaCa-2 cells on transwell® plates coated with collagen type I36. Although not 
conclusive, the invasive behavior through matrigel® was also demonstrated for MIA PaCa-2 and PANC-136. Our 
results indicate that MIA PaCa-2 and PANC-1 have EMT potential but that of PANC -1 is superior.
Concerning stem cell marker expression, both cell lines expressed population heterogeneity, with MIA PaCa-2 
(Fig. 3) cells expressing CD24−CD44+/++CD326−/+CD133/1−. It seems that the large cell population has the 
phenotype CD24−CD44++CD326−CD133/1− and the small cell population, CD24−CD44+CD326−/+CD133/1−. 
We also found that MIA PaCa-2 had two relevant CD44+ CD326− (48%) and CD44+CD326+ (35.5%) popu-
lations (Fig. 3I). The PANC-1 cell line expressed the phenotype CD24−/+CD44+CD326−/+CD133/1− (Fig. 4). 
CD24+CD44+CD326+ cancer cells display the ability to self-renew, generate different progeny and recapitulate 
Figure 4. Flow cytometry analysis of morphology and stem cell marker expression on PANC-1 tumor cells. 
(A) Dot plot FSC/SSC representative of the population P1 (blue) population; (B) Histogram representative 
of CD24 expression in P1; (C) Histogram representative of CD133/1 expression in P1; (D) Histogram 
representative of CD326 expression in P1; (E) Histogram representative of CD44 expression in P1.
www.nature.com/scientificreports/
8Scientific RepoRts | 6:21648 | DOI: 10.1038/srep21648
the phenotype of the tumor from which they were derived37. Cells negative for all three markers are not able to 
initiate pancreatic cancer until 104 or more cells are implanted38. Li et al.38 demonstrated that cells expressing 
CD24+CD44+CD326+ formed 6 tumors in 12 (50%) NOD/SCID mice after they were injected with 100 cells 
subcutaneously in their flank. With the single marker CD44+ or with the dual markers CD44+CD326+ , 4 out of 
16 (25%) animals developed tumors when injected with as few as 100 cells, and when the number of cells injected 
was increased (500 > 103 > 104), the dual marker combination CD44+CD326+ resulted in an enhanced tumori-
genic potential compared with the single marker CD44+. CD24+ cells are less tumorigenic than CD44+ cells, with 
1 out of 16 (6.25%) animals developing tumors when injected with as few as 100 cells. With CD326, 8 out of 18 
(44.4%) and 1 out of 18 (5.6%) animals developed tumors when injected with 500 CD326+ and 500 CD326− cells 
respectively. 103 CD24− cells were needed to generate a tumor when injected in 16 animals. We may presume 
that PANC-1 cells CD24+CD44+CD326+ are more tumorigenic than MIA PaCa-2 cells CD24−CD44+CD326+ , 
and that within MIA PaCa-2 the subpopulation CD44++CD326+ is more tumorigenic than the subpopulation 
CD44+CD326− . The surface marker CD133 was first reported to have the properties of CSCs in brain and colon 
cancer39 . Results from Hermann et al.40 revealed that 500 CD133+ cells injected in NOD/SCID mice were able 
to generate tumors. Lee et al.41 demonstrated that CD133+ cells had a higher tumorigenic potential and higher 
rates of metastasis to the lung than CD44+ cells, suggesting that CD133 is implicated in the aggressive behavior 
of pancreatic cancer. Neither MIA PaCa-2 nor PANC-1 expressed CD133, which seems to reduce their potential 
to metastasize. Despite these results, we should point out that the presence of stem cells cannot be inferred purely 
from surface marker expression. It is also known, for example, that the expression of the markers CD24, CD44 
and CD326 varies with the local microenvironment or niche42. Functional analyses should therefore be per-
formed, such as sphere formation assays43 or tumorigenesis in a transplantation setting in immunocompromised 
mice44,45.
KRAS, CDKN2A/p16INK4A, TP53, SMAD4/DPC4 and MSI analyses were used to throw light on the genetic 
carcinogenic mechanisms involved and identify possible sources of resistance to chemo and radiotherapy. 
Genotyping of MIA PaCa-2 (Fig. 5A) and PANC-1 (Fig. 6A) confirmed the presence of a homozygous (p.G12C; 
GGT > TGT) and a heterozygous missense mutation (p.G12D; GGT > GAT) in codon 12 of KRAS respec-
tively. This is a hotspot codon well known for interfering with the KRAS GTPase function, keeping the mole-
cule in its GTP-bound state, thus allowing uninterrupted activation of downstream effector pathways such as 
mitogen-activated protein kinase (MAPK)46. KRAS mutations confer drug resistance and lead to aggressive 
tumor growth and metastasis and a poor clinical outcome47. Moreover, tumor cells with a mutant KRAS are 
more radiation-resistant than are cells with the wild type of KRAS48. Some experiments have shown that farnes-
yltransferase inhibitor drugs, which prevent the post-translation processing of KRAS, essential for its appropriate 
cell-membrane localization, sensitize KRAS-mutated pancreatic cancer cells to radiation49.
CDKN2A, located on chromosome 9p21, encodes two proteins, P16 (INK4) and P14 (ARF). Both gene prod-
ucts have an independent first exon (exon 1-α and exon 1-β , respectively) but share exons 2 and 3, and are 
translated in different reading frames50. These proteins are involved in the negative control of cell proliferation: 
P16 (INK4) is a cyclin-dependent kinase inhibitor that induces G1 cell-cycle arrest by inhibiting Cdk4/6 and 
hence keeping the retinoblastoma protein (RB) in its active, dephosphorylated state; P14 (ARF) acts both at G1/S 
Figure 5. MIA PaCa-2 genetic profile. (A) Codon 12 of KRAS. The arrow signals a homozygous missense 
mutation (p.G12C; GGT > TGT); (B) Electrophoresis results from the amplification products of exons 1, 2 and 
3 of the gene CDKN2A/p16INK4A. A - cell line samples; B - contamination control, without DNA (blanks);  
C - normal samples (positive controls); 1, 2, 3 – exons; MPM - Molecular weight marker ϕ X174 DNA-HaeIII;  
(C) Exon 7 of TP53. The arrow signals a homozygous missense mutation (p.R248W; CGG > TGG).
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and G2/M phases in a TP53-dependent manner by destabilizing MDM2, the protein that maintains TP53 at low 
levels51. Concerning pancreatic tumors, the CDKN2A/p16INK4A gene is inactivated in 95% of invasive carcinomas, 
40% by homozygous deletion, 40% by an intragenic mutation coupled with loss of the second allele and 10–15% 
of cases by gene promoter hypermethylation. Tumors with CDKN2A deletion are larger and patients may have 
a survival period which is significantly shorter52. The genotyping of MIA PaCa (Fig. 5B) and PANC-1 (Fig. 5B) 
confirmed the presence of a homozygous deletion encompassing exons 1, 2 and 3 of the CDKN2A/p16INK4A gene, 
resulting in the indirect impairment of two important tumor suppressor proteins, RB and TP53, thus reproducing 
the effect of inactivating mutations.
TP53 function also seems to be disrupted in the two cell lines by missense mutations. The MIA PaCa-2 cell 
line showed a pathogenic missense variant in a hotspot codon (p.R248W). The PANC-1 cell line had a common 
polymorphism in exon 4 (p.P72R; rs1042522), located in the proline-rich domain of TP53 and possibly associ-
ated with differences in apoptosis induction53, and a pathogenic missense variant in an exon 8 hotspot codon 
(p.R273H; rs28934576). The two pathogenic variants, in exons 7 and 8, correspond to the DNA binding domain 
of TP53 and are known to disrupt its function as a transcription activator54,55. There is also some evidence that 
some TP53 mutations, including R273H, may induce gain of function effects, as knock-in mice expressing this 
mutation showed increased metastases compared with TP53 knock-out mice56 and a different cancer distribution. 
TP53 mutations were found in homozygosity in both cell lines, most probably due to the loss of heterozygosity 
(LOH) associated with chromosome 17p deletions including the wild-type allele, correlating with the loss of TP53 
suppressor function.
No changes were found in MIA PaCa-2 or PANC-1 concerning SMAD4/DPC4. Furthermore, the absence of 
MSI from all of the five markers analyzed suggests that the DNA mismatch repair (MMR) system is preserved57,58 
in the MIA PaCa-2 and PANC-1 cell lines.
Figure 6. PANC-1 genetic profile. (A) Codon 12 of KRAS. The arrow signals a heterozygous missense 
mutation (p.G12D; GGT > GAT); (B) Exon 4 of TP53. The arrow signals a homozygous missense mutation 
(p.P72R; CCC > CGC); (C) Exon 8 of TP53. The arrow signals a homozygous missense mutation (p.R273H; 
CGT > CAT).
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In conclusion, MIA PaCa-2 expresses polymorphism and PANC- 1 expresses pleomorphism. Polymophism 
and pleomorphism had not yet been described in previous studies, and they may introduce variations in the 
distribution of stem cell markers, making tumors more resistant to therapy. However, the association between 
stem cell markers and a specific type of cell morphology was not proved in this study. If this association exists, 
the treatment of these tumors may be even more complex than we currently assume, due to their heterogeneity.
It was confirmed that both cell lines have EMT differentiation but since PANC-1 has no E-cadherin, its behav-
ior is more aggressive with a greater metastasizing potential.
Both cell lines express neuroendocrine differentiation and SSTR2, and this had not been established in previ-
ous studies. It is precisely these features which make them suitable for pancreatic cancer neuroendocrine chemo-
therapy and peptide receptor radionuclide therapy.
Genes Codões Primers
Annealing 
temperatures
KRAS 12 e 13 F: 5′ -ACATGTTCTAATATAGTCAC-3′ 
54 °C
R: 5′ -CTATTGTTGGATCATATTCG-3′ 
61 F: 5′ -TTCCTACAGGAAGCAAGTAGT-3′ 
56 °C
R: 5′ -CATGGCATTAGCAAAGACTC-3′ 
CDKN2A/ p16INK4A Exon 1-alpha F: 5′ -ACC GGA GGA AGA AAG AGG AG-3′ 
58 °C
R: 5′ -TCA GGT AGC GCT TCG ATT CT-3′ 
Exon 2 F: 5′ -GTG AGG GGG CTC TAC ACA AG-3′ 
60 °C
R: 5′ -CAG CAC AGA AAG TTC AGC CC-3′ 
Exon 3 F: 5′ -TAC ATG CAC GTG AAG CCA TT-3′ 
56 °C
R: 5′ -TTC CCC CAC TAC CGT AAA TG-3′ 
TP53 Exon 4 F: 5′ -TGA CTG CTC TTT TCA CCC A T-3′ 
59 °C
R: 5′ -GGA AGC CAG CCC CTC AGG GC-3′ 
Exon 5 F: 5′ -AAC TCT GTC TCC TTC CTC TT-3′ 
58 °C
R: 5′ -GCC CCA GCT GCT CAC CAT CGC TA-3′ 
Exon 6 F: 5′ - TCT GAT TCC TCA CTG ATT GC-3′ 
54 °C
R: 5′ -CCA GAG ACC CCA GTT GCA AA-3′ 
Exon 7 F: 5′ - GCT GAG GAA GGA GAA TGG-3′ 
57 °C
R: 5′ -GTG ATG AGA GGT GGA TGG-3′ 
Exon 8 F: 5′ -CCT CTT AAC CTG TGG CTT CTC-3′ 
58 °C
R: 5′ -TAA CTG CAC CCT TGG TCT CCT-3′ 
SMAD4/DPC4 Exon 1 F: 5′ -CGTTAGCTGTTGTTTTTCACTG-3′ 
54 °C
R: 5′ -ACAGTATCTGAAGAGATGGAG-3′ 
Exon 2 F: 5′ -TGTATGACATGGCCAAGTTAG-3′ 
51 °C
R: 5′ -CAATACTCGGTTTTAGCAGTC-3′ 
Exon 3 F: 5′ -CTGAATTGAAATGGTTCATGAAC-3′ 
51 °C
R: 5′ -GCCCCTAACCTCAAAATCTAC-3′ 
Exon 4 F: 5′ -TTTTGCTGGTAAAGTAGTAGC
50 °C
R: 5′ -CTATGAAAGATAGTACAGTTAC
Exões 5 e 6 F: 5′ -CATCTTTATAGTTGTGCATTATC-3′ 
52 °C
R: 5′ -TAATGAAACAAAATCACAGGATG-3′ 
Exon 7 F: 5′ -TGAAAGTTTTAGCATTAGACAAC-3′ 
50 °C
R: 5′ -TGTACTCATCTGAGAAGTGAC-3′ 
Exon 8 F: 5′ -TGTTTTGGGTGCATTACATTTC-3′ 
52 °C
R: 5′ -CAATTTTTTAAAGTAACTATCTGA-3′ 
Exon 9 F: 5′ – TATTAAGCATGCTATACAATCTG-3′ 
50 °C
R: 5′ -CTTCCACCCAGATTTCAATTC-3′ 
Exon 10 F: 5′ -AGGCATTGGTTTTTAATGTATG-3′ 
52 °C
R: 5′ -CTGCTCAAAGAAACTAATCAAC-3′ 
Exon 11 F: 5′ -CCAAAAGTGTGCAGCTTGTTG-3′ 
54 °C
R: 5′ -CAGTTTCTGTCTGCTAGGAG-3′ 
Table 3.  Sequences of primers and annealing temperatures used in KRAS, CDKN2A/p16INK4A, TP53 and 
SMAD4/DPC4 amplification. F – Forward; R – Reverse. The same primers were used for the first PCR and for 
sequencing. The annealing temperatures correspond to those of the first PCR.
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Materials and Methods
Cell culture conditions. The MIA PaCa-2 (CRL-1420) and PANC-1 (CRL-1469) cell lines were both pur-
chased from American Tissue Cell Culture (ATCC, Manassas, VA, USA), and maintained under culture with 
Dulbecco’s Modified Eagle’s Medium (DMEM) (ATCC 30-2002, Manassas, VA, USA) supplemented with heat-in-
activated fetal bovine serum (FBS) (ATCC 30-2020) to a final concentration of 10% (v/v), at 37 °C and in a 5% 
CO2 atmosphere. In the case of MIA PaCa-2, horse serum (HS) (ATCC 30-2040, Manassas, VA, USA) to a final 
concentration of 2.5% was also added. Every 2–3 days cells were passaged (subcultivation ratio 1:3) using trypsin-
ization for cells to detach in order to maintain them in culture. A passage number of 20 was assumed for each cell 
line; after these 20 passages a new culture was started with the stock constituted after the reception of the cells 
from ATCC. This stock consisted of about 30 vials obtained during the first five passages; the vials were subse-
quently stored in liquid nitrogen, with complete growth medium 95% and DMSO 5%.
Immunohistochemistry. The immunohistochemical analysis was performed on sterile 10cm2 Lab-Tek 
Flaskette glass slides (VWR International, Ref. NUNC 177453) previously seeded with MIA PaCa-2 and PANC-1 
cells. As immunohistochemical markers, we selected epithelial (CK5/6, AE1/AE3, E-cadherin), mesenchymal 
(vimentin), endocrine (chromogranin A, CD56, synaptophysin) and hormonal (SSTR2, NTR1) antibodies. CK5.6, 
CD56 and synaptophysin were applied to the automated slide staining system BenchMark Ultra, with ultraView 
Universal DAB Detection kit 760-500, both from Ventana. The immunohistochemical staining of AE1/AE3, 
E-cadherin, vimentin, chromogranin A, SSTR2 and NTR1 was performed manually, the first four with the 
Ultravision Polyvalent HRP (TP-125-HL) kit from Lab Vision, and the last two with Bond™ Polymer Refine 
Detection from Leica Biosystems.
Primary antibodies against CK5.6 (clone D5/16B4; Cell Marque, California, USA), at a dilution of 1:50 for 
40 minutes, with skin cells as positive control, were applied to the sections and incubated at room temperature, as 
were ready-to-use AE1/AE3 (clone AE1/AE3; Novocastra Laboratories, Ltd., Newcastle, UK), for 30 minutes, with 
appendix cells as positive control; E-cadherin (clone 36B5; Novocastra Laboratories Ltd., Newcastle, UK), at a 
dilution of 1:100 for 30 minutes, with tonsil cells as positive control; vimentin (clone VIM 3B4; DakoCytomation, 
Glostrup, Denmark), at a dilution of 1:200 for 30 minutes, with colon cells as positive control; chromogranin A 
(clone DAK-A3; DakoCytomation, Glostrup, Denmark), at a dilution of 1:300 for 30 minutes, with pancreas cells 
as positive control; CD56 (clone 123C3; DakoCytomation, Glostrup, Denmark), at a dilution of 1:100 for 44 min-
utes, with colon cells as positive control; synaptophysin (polyclonal; Thermo Scientific, MA, USA), at a dilution of 
1:50 for 36 minutes, with thyroid cell as positive control; SSTR2 (polyclonal; abcam (ab9550), Cambridge, United 
Kingdom), at a dilution of 1:300 for 30 minutes, with kidney cells as positive control; and NTR1 (polyclonal 
H-130; Santa Cruz Biotechnology (sc-15311), California, United States), at a dilution of 1:250 for 30 minutes, with 
a pancreatic xenographt as positive control. They were washed with phosphate-buffered saline (PBS) (TP-125-PB; 
Lab Vision Corporation; Fremont CA; USA), after which slides were incubated with biotin-labeled secondary 
antibody, biotynilated goat anti-polyvalent (TP-125-BN; Lab Vision Corporation; Fremont CA; USA), for 15 min-
utes. Primary antibody binding was localized in tissues using peroxidase-conjugated streptavidin (TP-125-HR; 
Lab Vision Corporation; Fremont CA; USA), and 3,3′ -diaminobenzidine tetrahydrochloride (DAB) (RE7190-K; 
Novocastra Laboratories Ltd., Newcastle, UK) was used as chromogen, according to the manufacturer’s instruc-
tions. Hematoxylin was used to counterstain the slides, which were then dehydrated and mounted. As negative 
controls, we used positive controls without the addition of a primary antibody.
The intensity of the staining was graded semi-quantitatively on a three point scale [+ (low), + + (medium), 
+ + + (high)] and the percentage of immunostained cells was also registered. The final score was obtained by estab-
lishing a scale, having adopted the following threshold of reactivity (cut-off  ) : − (0%); + (< 10%), + + (10–75%), 
+ + + (> 75%).
Flow Cytometry. Flow cytometry was used for identification and clarification of the cell population for each 
cell line. MIA Paca-2 and PANC-1 cell lines were dissociated using 0.25% trypsin/0.53 mM EDTA in Hanks 
Marker GenBank Ref
Repetitions
Primer Fluorochrome Product (bp)Location
BAT25 U41210 26A F1: 5′ -TCGCCTCCAAGAATGTAAGT-3′ 6-FAM 110–130
CKIT; intron 5 R: 5′ -TCTGCATTTTAACTATGGCTC-3′ 
BAT26 L04143 25T F2: 5′ -TGACTACTTTTGACTTCAGCC-3′ TET/VIC 100–120
MSH2: intron 16 R: 5′ -AACCATTCAACATTTTTAACCC-3′ 
NR21 XM033393 21(T) F3: 5′ -TAAATGTATGTCTCCCCTGG-3′ HEX/NED 103
SLC7A8; 5′ UTR R: 5′ -ATTCCTACTCCGCATTCACA-3′ 
NR22 L38961 22(T) F1: 5′ -GAGGCTTGTCAAGGACATAA-3′ FAM 142
ITM1; 3′ UTR R: 5′ -AATTCGGATGCCATCCAGTT-3′ 
NR24 X60152 24(T) F3: 5′ -CCATTGCTGAATTTTACCTC-3′ HEX/NED 132
ZNF-2; 3′ UTR R: 5′ -ATTGTGCCATTGCATTCCAA-3′ 
Table 4.  Sequences of primers used in the detection of microsatellite instability. F – Forward; R – Reverse; 
bp – base pairs of the amplified product. The microsatellites were amplified with a multiplex PCR and with an 
annealing temperature of 55 °C.
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Balanced Salt Solution (ATCC 30-2101) for 5 minutes at 37 °C. Trypsin was then inhibited with DMEM comple-
mented with a 10% FBS culture medium (MIA PaCa-2 and PANC-1) and 2.5% HS (MIA PaCa-2). Approximately 
0.5 × 106 cells were transferred to a 5 ml tube (BD Biosciences, San Jose, CA, USA) and washed twice with 
Dulbecco’s Phosphate Buffered Saline (PBS). Cells were resuspended in 500 μ l PBS, and samples were acquired 
on a FACSCanto II flow cytometer (BD Biosciences) and analyzed with FACSDiva software (BD Biosciences). 
Thus, it was possible to obtain, select and represent the cells graphically in the form of a dot plot as a function of 
forward-scattered (FSC) and side-scattered light (SSC). We used the 7-AAD (7-amino-actinomycin-D) as a dead 
cell marker to confirm the presence of the non-viable population, whereby the livings cells were quantified by 
exclusion.
Flow cytometry was also used for the identification of pancreatic cancer stem cells markers10, such as CD24, 
CD44, CD133/1 and CD326. After dissociation with trypsin and subsequent neutralization with DMEM comple-
mented with FBS and HS, cells were resuspended in 500 μ l PBS and, for MIA PaCa-2, 20 μ l of the following mon-
oclonal antibodies were added: anti-CD24-PE (clone 32D12, Miltenyi Biotec), anti-CD44-PerCP/Cy5.5 (clone 
IM7, BD Pharmingen), anti-CD133/1-APC (clone AC133, Miltenyi Biotec) and anti-CD326-PE-Cy7 (clone 9C4, 
Miltenyi Biotec). For PANC-1, 20 μ l of the following monoclonal antibodies were added: anti-CD24-FITC (clone 
ML5, BD Pharmingen), anti-CD44-APC (clone BJ18, Biolegend), anti-CD133/1-PE (clone AC133, Miltenyi 
Biotec) and anti-CD326-PE-Cy7 (clone 9C4, Biolegend). The mixture was incubated for 20 minutes at room 
temperature and protected from light. After incubation, cells were washed twice with PBS and resuspended in 
500 μ l PBS. For MIA PaCa-2, rat anti-mouse IgG1-PE, IgG2b-PerCP/Cy5.5, IgG1-APC and IgG2b-PE-Cy7 were 
used as isotype negative controls (Biolegend) for CD24, CD44, CD133/1 and CD326 respectively. For PANC-1, 
rat anti-mouse IgG2a-FITC, IgG1-APC, IgG1-PE, and IgG2b-PE-Cy7 were used as isotype negative controls 
(Biolegend) for CD24, CD44, CD133/1 and CD326 respectively. Samples were acquired on a FACSCanto II flow 
cytometer (BD Biosciences) and analyzed with FACSDiva software (BD Biosciences).
PCR and sequencing. By determining the genetic profile of cell lines MIA PaCa-2 and PANC-1, this study 
aimed to investigate the most frequent mutations in pancreatic ductal adenocarcinoma. DNA was extracted from 
2 to 5 × 106 viable cells of the MIA PaCa-2 and PANC-1 cell lines using the QIAamp DNA mini Kit (Qiagen, 
Hilden, Germany), and from the blood of healthy control individuals using the QIAamp DNA blood mini Kit 
(Qiagen, Hilden, Germany), according to the manufacturer’s protocol.
KRAS (codons 12, 13 and 61), TP53 (exons 4 to 8) and SMAD4/DPC4 (codifying exons 2 to 11) were studied 
by sequencing using primers and cycling conditions, as described in Table 3. Sequencing was performed using 
the ABI PRISM BigDye v1.1 Terminator Cycle Sequencing Kit (Applied Biosystems, Foster City, CA, USA), the 
same primers as in PCR, and an ABI PRISM 3130 Genetic Analyzer (Applied Biosystems, Foster City, CA, USA). 
Results were analyzed with sequencing analysis software v 5.2 (Applied Biosystems, Foster City, CA, USA). For 
CDKN2A/p16INK4A, as the most frequent mutation is the homozygous deletion, we only proceeded to PCR and 
thus three exons, exons 1-α , 2 and 3, were amplified from the DNA of cell lines and of a healthy control using 
primers and the conditions described in Table 3. MSI testing was carried out with a multiplex PCR amplifi-
cation of 5 quasi monomorphic mononucleotide repeats (BAT25, BAT26, NR21, NR22 and NR24) with DNA 
from the cell lines and from the healthy control. Briefly, 40 ng of genomic DNA were amplified in a 25 μ l reac-
tion using primers at 0.16 μ M, MgCl2 at 1.5 mM, dNTPs at 200 μ M and 0.2 U recombinant Taq DNA polymer-
ase (Fermentas, Thermo Scientific, MA, USA). Primer sequences and PCR cycling conditions are described in 
Table 4. A volume varying from 0.1 to 1 μ l of amplified PCR product was added to 25 μ l of formamide and 
1 μ l of internal fluorescence standard-sized GS500LIZ, incubated for 5 minutes at 95 °C and then applied to the 
ABI PRISM 3130 Genetic Analyzer using the POP7 polymer. Automatic fragment analysis was carried out with 
GeneMapper software v3.7 (Applied Biosystems, Foster City, CA, USA). The presence of three or more mutant 
alleles was considered to indicate the presence of MSI-high (MSI-H)59. The absence of MSI implies the absence 
of mutations in the MMR system.
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